DK3621960T3 - Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere - Google Patents

Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere Download PDF

Info

Publication number
DK3621960T3
DK3621960T3 DK18727589.6T DK18727589T DK3621960T3 DK 3621960 T3 DK3621960 T3 DK 3621960T3 DK 18727589 T DK18727589 T DK 18727589T DK 3621960 T3 DK3621960 T3 DK 3621960T3
Authority
DK
Denmark
Prior art keywords
thienpyridins
iraq4
benzothiophenes
inhibitors
iraq4 inhibitors
Prior art date
Application number
DK18727589.6T
Other languages
English (en)
Inventor
Saleem Ahmad
Ling Li
Lidet A Negash
John Hynes
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3621960T3 publication Critical patent/DK3621960T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK18727589.6T 2017-05-11 2018-05-10 Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere DK3621960T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762504956P 2017-05-11 2017-05-11
PCT/US2018/031945 WO2018209012A1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors

Publications (1)

Publication Number Publication Date
DK3621960T3 true DK3621960T3 (da) 2021-09-27

Family

ID=62245511

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18727589.6T DK3621960T3 (da) 2017-05-11 2018-05-10 Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere

Country Status (27)

Country Link
US (1) US10829496B2 (da)
EP (1) EP3621960B1 (da)
JP (1) JP7154229B2 (da)
KR (1) KR102604900B1 (da)
CN (1) CN110612298B (da)
AR (1) AR111689A1 (da)
AU (1) AU2018265130B2 (da)
BR (1) BR112019023290A2 (da)
CA (1) CA3062602A1 (da)
CL (1) CL2019003198A1 (da)
CO (1) CO2019012494A2 (da)
CY (1) CY1124552T1 (da)
DK (1) DK3621960T3 (da)
EA (1) EA039189B1 (da)
ES (1) ES2889926T3 (da)
HR (1) HRP20211583T1 (da)
HU (1) HUE056493T2 (da)
IL (1) IL270494B (da)
LT (1) LT3621960T (da)
MX (1) MX2019012929A (da)
PE (1) PE20191817A1 (da)
PL (1) PL3621960T3 (da)
PT (1) PT3621960T (da)
RS (1) RS62430B1 (da)
SI (1) SI3621960T1 (da)
TW (1) TW201900640A (da)
WO (1) WO2018209012A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein compounds and their uses
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
AU2018396142A1 (en) 2017-12-26 2020-07-16 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. CRBN LIGANDS AND THEIR USES
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
CN114174304B (zh) * 2019-07-23 2024-05-17 百时美施贵宝公司 可用作irak4抑制剂的噻吩并吡啶基化合物和噻唑并吡啶基化合物
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス, インコーポレイテッド Irak分解剤およびそれらの使用
CN111285844B (zh) * 2020-02-24 2022-08-12 河南师范大学 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
IL314437A (en) 2022-01-31 2024-09-01 Kymera Therapeutics Inc IRAK joints and their uses

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
JP4541695B2 (ja) 2001-06-15 2010-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとしての5−(2−アミノピリミジン−4−イル)ベンズイソキサゾール
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
JP4529685B2 (ja) 2002-06-28 2010-08-25 アステラス製薬株式会社 ジアミノピリミジンカルボキサミド誘導体
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CN1820001A (zh) 2003-07-10 2006-08-16 神经能质公司 经取代的杂环二芳基胺类似物
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
CN101171052A (zh) 2005-03-09 2008-04-30 先灵公司 抑制ksp驱动蛋白活性的化合物
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2636242A1 (en) 2006-01-30 2008-05-29 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
AU2008258508A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JP5254693B2 (ja) 2008-07-30 2013-08-07 三菱重工業株式会社 Ni基合金用溶接材料
US20110230467A1 (en) 2008-11-21 2011-09-22 Astellas Pharma Inc. 4,6-diaminonicotinamide compound
BRPI0920966B1 (pt) 2008-11-28 2022-03-03 Kowa Company Ltd Derivado de piridina-3-carboxiamida, seu uso, inibidor de jak3 e composição farmacêutica
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
NZ598455A (en) 2009-09-03 2014-03-28 Allergan Inc Compounds as tyrosine kinase modulators
EP2493863B1 (en) 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
CN102971304A (zh) 2010-02-01 2013-03-13 日本化学医药株式会社 Gpr119激动剂
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
MX2013012588A (es) 2011-04-29 2014-05-20 Icahn School Med Mount Sinai Inhibidores de cinasa.
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
EP2802579B1 (en) 2012-01-13 2016-04-13 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
EP2802576B1 (en) * 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
JP6204484B2 (ja) 2012-11-08 2017-09-27 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼモジュレーターとして有用なヘテロアリール置換ピリジル化合物
ES2616812T3 (es) * 2012-11-08 2017-06-14 Bristol-Myers Squibb Company Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
BR112015010244A8 (pt) 2012-11-08 2019-10-01 Bristol Myers Squibb Co compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
GEP20186887B (en) 2014-04-04 2018-08-27 Pfizer Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
US10040802B2 (en) * 2015-03-12 2018-08-07 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of IRAK4 activity
EP3268367B8 (en) * 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
TW201713663A (zh) 2015-06-24 2017-04-16 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
US10294229B2 (en) 2015-06-24 2019-05-21 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
CN107949559B (zh) 2015-08-27 2020-12-11 辉瑞公司 作为irak4调节剂的双环稠合杂芳基或芳基化合物

Also Published As

Publication number Publication date
LT3621960T (lt) 2021-10-11
WO2018209012A1 (en) 2018-11-15
PL3621960T3 (pl) 2021-11-08
AU2018265130A1 (en) 2020-01-02
PE20191817A1 (es) 2019-12-27
JP7154229B2 (ja) 2022-10-17
CA3062602A1 (en) 2018-11-15
US20200062777A1 (en) 2020-02-27
HRP20211583T1 (hr) 2022-01-07
IL270494B (en) 2022-04-01
ES2889926T3 (es) 2022-01-14
SI3621960T1 (sl) 2021-11-30
EP3621960A1 (en) 2020-03-18
EP3621960B1 (en) 2021-08-04
CY1124552T1 (el) 2022-07-22
BR112019023290A2 (pt) 2020-06-16
CO2019012494A2 (es) 2020-01-17
CN110612298A (zh) 2019-12-24
TW201900640A (zh) 2019-01-01
US10829496B2 (en) 2020-11-10
MX2019012929A (es) 2020-01-14
KR102604900B1 (ko) 2023-11-21
PT3621960T (pt) 2021-09-16
AR111689A1 (es) 2019-08-07
HUE056493T2 (hu) 2022-02-28
JP2020519596A (ja) 2020-07-02
EA201992674A1 (ru) 2020-04-06
RS62430B1 (sr) 2021-11-30
CN110612298B (zh) 2023-05-05
KR20200004871A (ko) 2020-01-14
AU2018265130B2 (en) 2022-03-24
CL2019003198A1 (es) 2020-03-20
EA039189B1 (ru) 2021-12-15

Similar Documents

Publication Publication Date Title
DK3621960T3 (da) Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere
DK3728254T3 (da) Benzylamin-substituerede pyridopyrimidinoner og derivater som sos1-inhibitorer
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3328849T5 (da) 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
DK3307707T3 (da) Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider
DK3319434T3 (da) Herbicidsammensætning, der omfatter cinmethylin og pethoxamid
DK3347472T3 (da) Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf.
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3672976T3 (da) Bcl-2-hæmmere
DK3580220T3 (da) Aminotriazolpyridiner som kinasehæmmere
DK3482760T3 (da) Kombination, der omfatter en ep4-antagonist og en immuncheckpoint-hæmmer
DK3640207T3 (da) Molekularsi scm-15, syntesefremgangsmåde dertil og anvendelse deraf
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3712150T3 (da) Makrocyklisk forbindelse, der tjener som wee1-hæmmer, og anvendelser deraf
DK3630744T3 (da) Pyrazol-magl-inhibitorer
DK3704118T3 (da) Aminoimidazopyrazin som kinasehæmmere
BR112017005511A2 (pt) inibidores da histona-desmetilase.
DK3700907T3 (da) Hidtil ukendte pyrazolo-pyrrolo-pyrimidindion-derivater som p2x3-inhibitorer
DK3277682T3 (da) 6-morpholinyl-2-pyrazolyl-9h-purinderivater og anvendelse heraf som pi3k- hæmmere